Apellis Downgraded by Roth, MKM after Biogen Deal Roth and MKM downgraded Apellis on Apr 2, 2026; 2 analysts cut ratings after Biogen acquisition, raising near-term valuation and liquidity questions.

Apellis Downgraded by Roth, MKM after Biogen Deal: Roth and MKM downgraded Apellis on Apr 2, 2026; 2 analysts cut ratings after Biogen acquisition, raising near-term valuation and liquidity questions. 👈 Read full analysis #Apellis #Biogen #Roth #MKM #Downgrade

Article image

Biogen acquires Apellis for $5.6B to expand kidney drugs 💰💉. A major biotech move! Let's see how biotech and healthcare stocks react... #Biogen #Apellis #Pharma #Markets #Investing #BreakingBroke

Article image

Biogen acquista Apellis per 5,6 miliardi di dollari per espandere i farmaci renali 💰💉. Una grande mossa nel settore biotech! Vediamo come reagiranno i titoli biotech e sanitari... #Biogen #Apellis #Farmaceutica #Borsa #Investimenti #TachicardiaTrading

In today's second sizeable M&A deal, #Biogen has agreed to buy #Apellis for around $5.6 billion, seeking to get control of two approved therapies for #kidney and #eyedisorders.

buff.ly/Svvq4g9

Apellis stock rises after $300 million royalty deal with Sobi Investing.com -- Apellis Pharmaceuticals Inc (NASDAQ:APLS) stock rose 3.2% after the company announced a royalty agreement with Sobi that could bring in up to $300 million in non-dilutive funding. Under the deal, Apellis will receive $275 million upfront in exchange for 90% of its future ex-U.S. royalties for Aspaveli (systemic pegcetacoplan), with potential for an additional $25 million in milestone payments tied to European regulatory approvals for C3G and IC-MPGN indications. The agreement includes performance-based caps, after which all ex-U.S. royalties would revert to Apellis. The transaction allows Apellis to maintain its exclusive U.S. commercialization rights for the drug, which is marketed as EMPAVELI in the United States. The company is eligible for tiered royalties on ex-U.S. sales ranging from high teens to high twenties percentage points under the companies’ 2020 collaboration agreement. "This transaction reflects our shared conviction in the potential of Aspaveli/EMPAVELI to transform the treatment landscape for patients with rare diseases," said Timothy Sullivan, chief financial officer at Apellis, noting that the funding "provides significant operational flexibility" as the company approaches sustainable profitability. Aspaveli/EMPAVELI is currently approved in the U.S., European Union, and other global markets for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The drug is under regulatory review in both the EU and U.S. for treating C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, with a CHMP opinion expected before year-end in Europe and a PDUFA date of July 28, 2025, in the U.S. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Apellis #StockMarket #Investing #FinanceNews #RoyaltyDeal

Sobi Announces Significant Changes in Partnership with Apellis for Aspaveli Royalties Sobi and Apellis Pharmaceuticals have revised their agreement concerning Aspaveli royalties, marking a transformative step in their collaboration.

Sobi Announces Significant Changes in Partnership with Apellis for Aspaveli Royalties #USA #Stockholm #Sobi #Aspaveli #Apellis

Sobi Announces Significant Restructuring of Royalty Agreement with Apellis for Aspaveli Sobi has restructured its existing royalty agreement with Apellis Pharmaceuticals, reducing its royalty payment obligations significantly, part of a strategic partnership.

Sobi Announces Significant Restructuring of Royalty Agreement with Apellis for Aspaveli #Sweden #Stockholm #Sobi #Aspaveli #Apellis

Sobi and Apellis Reveal Long-Term Benefits of Aspaveli® in Kidney Disease Study Sobi and Apellis present promising results from the Phase 3 study of Aspaveli® for rare kidney diseases, showing sustained efficacy over one year.

Sobi and Apellis Reveal Long-Term Benefits of Aspaveli® in Kidney Disease Study #Sweden #Stockholm #Sobi #Aspaveli #Apellis

The Rising Market Potential of EMPAVELI and Its Impact on Complement Inhibitor Therapies A look at the growing demand for EMPAVELI, a complement inhibitor therapy, and its significance in treating conditions like PNH and more.

The Rising Market Potential of EMPAVELI and Its Impact on Complement Inhibitor Therapies #USA #Las_Vegas #PNH #Apellis #EMPAVELI

EMA Validates Aspaveli® Application for Extended Use in Rare Kidney Disease Treatment The European Medicines Agency has validated an application for Aspaveli® to treat C3 glomerulopathy and IC-MPGN, rare kidney diseases without existing therapies.

EMA Validates Aspaveli® Application for Extended Use in Rare Kidney Disease Treatment #Sweden #Stockholm #Aspaveli #C3G #Apellis